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Abstract
Herpesviruses infect most humans. Their infections can be associated with pathological conditions and significant changes
in T cell repertoire but evidences of symbiotic effects of herpesvirus latency have never been demonstrated. We tested the
hypothesis that HCMV and EBV-specific CD8 T cells contribute to the heterologous anti-viral immune response. Volume of
activated/proliferating virus-specific and total CD8 T cells was evaluated in 50 patients with acute viral infections: 20 with
HBV, 12 with Dengue, 12 with Influenza, 3 with Adenovirus infection and 3 with fevers of unknown etiology. Virus-specific
(EBV, HCMV, Influenza) pentamer+ and total CD8 T cells were analyzed for activation (CD38/HLA-DR), proliferation (Ki-67/Bcl-
2low) and cytokine production. We observed that all acute viral infections trigger an expansion of activated/proliferating CD8
T cells, which differs in size depending on the infection but is invariably inflated by CD8 T cells specific for persistent
herpesviruses (HCMV/EBV). CD8 T cells specific for other non-related non persistent viral infection (i.e. Influenza) were not
activated. IL-15, which is produced during acute viral infections, is the likely contributing mechanism driving the selective
activation of herpesvirus specific CD8 T cells. In addition we were able to show that herpesvirus specific CD8 T cells
displayed an increased ability to produce the anti-viral cytokine interferon-c during the acute phase of heterologous viral
infection. Taken together, these data demonstrated that activated herpesvirus specific CD8 T cells inflate the activated/
proliferating CD8 T cells population present during acute viral infections in human and can contribute to the heterologous
anti-viral T cell response.
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Introduction
Over the course of the human lifetime, we are exposed to and
infected by many different organisms which may be eliminated or
may persist. The co-existence of microorganisms in humans is
mainly perceived to have negative consequences for health and
wellbeing, but examples of potential symbiotic relationship
between the host and microbes start to be recognized [1,2].
Classic examples of microorganisms establishing persistent
infections in humans are Epstein Barr virus (EBV) and human
cytomegalovirus (HCMV) which are both from ubiquitous
herpesviridae family of viruses which infect more than 90% of the
human populations. These viruses are associated with the
development of specific tumors (i.e. Burkitt’s Lymphoma) and
they can reactivate with significant pathological consequences in
immunocompromised hosts [3,4]. Nevertheless, in most of the
cases, herpesvirus infections are subclinical and well tolerated,
even though they cause a robust distortion of T cell repertoire
[5,6] with HCMV and EBV-specific CD8 T cell known to
represent up to 20% of total CD8 T cell population [7,8,9]. Our
inherent effort to maintain such a large population of virus-specific
T cells, is seen as a necessity to suppress CMV and EBV
reactivation in humans [9,10,11]. This would imply that the sole
function of herpesvirus specific memory effector CD8 T cells is to
act against CMV and EBV infected cells. However, evidence in
animal models have shown that effector or memory CD8 T
cells can provide immune protection against infection with
unrelated intracellular pathogens through production of Interferon
c (IFN-c) [12]. Such data open the possibility that the large
population of HCMV and EBV-specific CD8 T cells present in
humans might contribute to the immunological response against
other pathogens.
Thus, we set out to evaluate whether CD8 T cells specific for
herpesviruses can contribute to the anti-viral T cell response
triggered by heterologous acute viral infection in humans. CD8 T
cell responses to acute viral infections were analyzed sequentially
(from onset to recovery) by measuring the population of activated/
proliferating CD8 T cells in patients with acute Hepatitis B Virus
(HBV), influenza, dengue and adenovirus infections. The
combination of activation and proliferation markers (CD38,
HLA-DR, Ki-67 and Bcl-2) expressed by CD8 T cells have been
recently proposed to identify the whole population of virus-specific
effector CD8 T cells induced by viral infection [13]. These results
were obtained in subjects receiving attenuated virus vaccines
(Smallpox and Yellow Fever), and activation (CD38/HLA-DR)
and proliferation markers (Ki-67/Bcl-2 low) were only expressed
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different specificities.
In contrast, we demonstrate here that acute symptomatic viral
infections trigger an expansion of activated/proliferating CD8 T
cell populations of variable sizes, comprising CD8 T cells specific
for the infecting virus but these populations are also invariably
inflated by CD8 T cells specific for persistent herpesvirus
infections. The increased sensitivity of HCMV and EBV-specific
CD8 T cells to IL-15 is the likely explanation of this in vivo
observation. In addition, HCMV and EBV specific CD8 T cells
demonstrate, at the peak of acute infection, an increased ability to
secrete IFN-c suggesting that they might functionally contribute to
the heterologous acute anti-viral immunity.
Results
The size of anti-viral CD8 T cell response in acute
hepatitis B
We initially evaluated the size and the expansion kinetics of
CD8 T cell population during acute hepatitis B infection. The
frequency and quantity of CD8 T cells expressing CD38/HLA-
DR and Ki-67/Bcl-2 phenotypic markers was analyzed in 20
patients with acute hepatitis B. Samples were collected at multiple
time points from onset of disease (HBsAg+, ALT.1000 U/L) to
full recovery (HBsAg- at least 1 month after onset).
A remarkably large expansion of activated CD8 T cell pool was
detected. CD38/HLA-DR markers were expressed by approxi-
mately a quarter of total CD8 T cells (mean 23%, range 12–68%)
at the onset of clinical hepatitis. The frequency of CD38/HLA-
DR+ CD8 T cells decreased consistently at the second time point
(8–10 days later, mean 12%; range 4–22%) and at the time of
recovery it returned to the normal level (mean 3%, range 0.9–
10%), detectable in healthy controls (Figure 1, left panel). CD8 T
cells co-expressing Ki-67 and low Bcl-2 followed identical kinetics.
The peak of Ki-67/Bcl-2 low CD8 T cells was detected at the
onset of disease (mean 14%, range 4.5–27% of total CD8 T) and
contracted abruptly after 10 days (mean 5%, range 0.8–11%) and
at the resolution minimal proliferation was detected (mean 0.8%,
range 0.4–1.6%) (Figure 1, right panel).
Antigen-specificity of the activated/proliferating CD8 T
cell population
To analyze whether the population of activated/proliferating
CD8 T cells included HBV-specific CD8 T cells, HBV-specific
pentamers were used to directly visualize these cells in 5 HLA-
A201+ patients. Figure 2 A and B shows that the expression of
activation markers of HBV-specific CD8 T cells followed the
kinetics of expression of the total CD8 T cell population. HBV-
pentamer+ CD8 T cells expressed activation markers and
Author Summary
The majority of humans are infected by herpesviruses,
such as Epstein-Barr virus and Human Cytomegalovirus,
which rarely cause severe pathology but heavily distort the
human T cell repertoire. Up to 20% of cytotoxic T cells can
be specific to Epstein-Barr and Cytomegalovirus. It is
believed that all these herpesvirus specific T cells are
needed to control the persistent infection. However, it has
not been explored whether these T cells can contribute to
the immune response to a new viral infection. To
investigate this possibility, we analyzed the volume of
activated virus-specific and total T cells in patients with
acute hepatitis B, dengue, influenza and adenovirus
infections. We observed that all acute viral infections
trigger an expansion of activated T cell population, part of
which is specific to infecting agent, and the other part to
herpesviruses. Our study provides evidence that persistent
herpesvirus infections alter the composition of the T cell
population which is activated during new acute viral
infection.
Figure 1. Activated and proliferating CD8 T cells during acute hepatitis B infection. Longitudinal CD38/HLA-DR (left) and Ki-67/Bcl-2 (right)
expression on total CD8 T cells in patients with acute HBV infection (n=20) is shown. Ki-67/Bcl-2 expression was done in 9 out of 20 patients. FACS
contour plots were gated on CD3/CD8 positive cells. Percentages of double positive cells are shown. The arrow indicates the level of activation/
proliferation found in healthy controls (the average of 5). White bars indicate the mean serum ALT levels, shaded area shows the mean serum HBV
DNA of the patients tested.
doi:10.1371/journal.ppat.1001051.g001
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(Figure 2 A and B). These results demonstrate that HBV-specific
CD8 T cells are represented within the total population of
activated/proliferating total CD8 T cells.
Then we tested whether CD8 T cell specific for other common
viruses (CMV, EBV, influenza) quantitatively contribute to the
total pool of activated/proliferating CD8 T cells. A set of HCMV,
EBV or Influenza pentamers (Supplementary Table S1) was used
to detect CD8 T cells specific for these common infections. We
visualized a sizeable ex vivo frequency of HCMV, Influenza and
EBV-specific CD8 T cells in 13 acute hepatitis B patients and their
expression of CD38/HLA-DR and Ki-67 was tested at the onset
of acute hepatitis and after recovery.
A remarkably different profile of CD8 T cell activation was
detected in relation to the CD8 T cell specificity. While influenza-
specific CD8 T cells were neither activated (8 out of 8 patients) nor
proliferating (5 out of 5 tested patients) at all time points (Figure 3
A and Supplementary Figure S1), HCMV and EBV-specific CD8
T cells were activated (HCMV mean 12.5%; EBV mean 30%) and
proliferating (HCMV mean 4.9%; EBV mean 8%) (Tables 1–2
and Figure 3 A) in all the acute HBV patients where such cells
were detectable. The expression of CD38/HLA-DR and Ki-67
markers in HCMV and EBV-specific CD8 T cells followed the
same expression kinetics of total and HBV-specific CD8 T cells
and contracted after recovery as shown on Figure 3 B (patient 12).
The differential phenotype of CD8 T cells specific for different
viruses during acute hepatitis B was well represented in a patient
(patient 10, Supplementary Figure S1) where the different CD8 T
cells specificities co-exist in different activation states. As already
shown in Figure 2, at the peak of acute hepatitis, HBV-specific
CD8 T cells are mostly activated (77%) and proliferating (65%). At
the same time point, a proportion of HCMV-specific CD8 T cells
are also expressing activation (20%) and proliferation (6%)
markers, while influenza-specific are in a complete resting
phenotype. Taken together, these data demonstrated that, at least
in acute hepatitis B infection, a sizable proportion of CD8 T cells
specific for persistent viruses are activated during acute heterol-
ogous infection.
Activated HCMV/EBV specific CD8 T cells during acute
viral infections
Evidence of activation of unrelated virus specific CD8 T cells
has been also reported in HIV infection [14], but our results
clearly differ from the ones obtained in attenuated virus vaccine
recipients [13], where activation of Influenza, HCMV and EBV
was not reported. Thus we tested whether our observation was
peculiar to acute HBV infection or whether it represents a
common feature in other acute viral infections in human.
Samples from patients with acute Dengue (n 12), Influenza A (n
12), Adenovirus (n 3) infections were collected at the onset of
disease (represented in these patients by fever .38u C), after 5–7
days and after recovery (,21 days) and frequency of CD8 T cell
population expressing activation (CD38/HLA-DR) and prolifer-
ation (Ki-67) markers was measured (Figure 4 A). Differences in
the magnitude and kinetics among diseases with different etiology
were found. Adenoviral infection elicited a minimal activation of
CD8 T cell population (mean 3.5%), which is only slightly higher
than that of healthy individuals (mean of 5 healthy controls 2.4%).
In addition, the peak frequency of activated total CD8 T cells in
dengue and influenza infections is detected 5–7 days after onset of
Figure 2. Activation and proliferation of HBV-specific T cells during acute HBV infection. A) CD38/HLA-DR and Ki-67 expression on HBV
core18–27 pentamer + CD8 T cells at the onset of disease and after resolution (+35 days) in a representative patient. B) Percentages of HBV-pentamer
+ CD8 T cells expressing CD38/HLA-DR and Ki-67 in 5 patients over time.
doi:10.1371/journal.ppat.1001051.g002
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PLoS Pathogens | www.plospathogens.org 3 August 2010 | Volume 6 | Issue 8 | e1001051Figure 3. Activation of HCMV and EBV-specific CD8 T cells during acute hepatitis B infection. A) Frequencies of total, and Influenza,
HCMV, EBV specific CD8 T cells expressing CD38/HLA-DR and Ki-67 at the onset of acute hepatitis B. Data shown only for the patients where virus-
specific CD8 T cells were visualized (P7, P9, P10–13, P22–28). The numbers in brackets indicate the number of patients tested. P value was calculated
using Mann Whitney test. The differences are considered significant when the P value ,0.05. B) Phenotypic profile of total CD8 T and EBV-specific
(BZLF-1 190–197+ EBNA-3A 193–201) CD8 T cells over time in a representative acute hepatitis B patient (P 12). Percentages of respective gates/upper
left quadrants are shown.
doi:10.1371/journal.ppat.1001051.g003
Inflation of Antiviral CD8+ T Cell Response
PLoS Pathogens | www.plospathogens.org 4 August 2010 | Volume 6 | Issue 8 | e1001051fever unlike that of HBV, where the peak frequency is seen at the
onset of disease (Figure 4 A). These different profiles are
compatible with the fact that the onset of disease in acute hepatitis
(jaundice) is represented by liver injury and coincides with the
peak of adaptive immune response [15,16] while dengue and
influenza infections trigger a strong innate immune reaction
(febrile status being a clinical manifestation) and thus, in these
infections, full maturation of virus-specific adaptive immunity is
expected to peak ,5–7days after infection.
Nevertheless, despite the lower quantity of total activated CD8
T cells in dengue, influenza, adenovirus patients as well as in 3
subjects with fever of unidentified etiology, the CD38/HLA-DR
expression profile on HCMV or EBV specific CD8 T cells was
similar to that in acute HBV infection. Figure 4 B summarizes the
results obtained in the patients with the indicated pathologies,
where a sizeable ex vivo frequency of HCMV or EBV specific
CD8 T cells was detected. HCMV and EBV specific CD8 T cells
(lower panel) express activation markers to a level even higher to
what is detected in the global CD8 T cells populations (upper
panel). Unfortunately, the paucity of the cells obtained in these
patients didn’t allow us to analyze also Ki-67 expression on
HCMV and EBV specific CD8 T cells, but overall these results
demonstrate that activation of CD8 T cells specific for persistent
viral infection (HCMV-EBV) is a constitutive feature of acute anti-
viral immunity in human.
Interestingly, we were able to study a patient with acute
influenza infection in whom, influenza-specific CD8 T cell
expansion didn’t coincide with the profile of total activated CD8
T cells (Figure 4 C, P14). In this subject, the influenza-specific
CD8 T cells (specific for matrix protein 58–66 epitope) could be
visualized only 5 days after onset of symptoms. In contrast,
HCMV-specific (pp65 123–131) CD8 T cell frequency was
comparatively constant at different time points (1.7% onset;
1.8% +5 days; 1.4% +14 days), and already co-expressed
activation markers (30%) at the onset of disease (Figure 4 C).
Thus, in this patient, the whole CD38/HLA-DR+ population
before the expansion of the CD8 T cells specific for the acutely
infected virus seems to be composed of herpesvirus-specific
activated CD8 T cells.
Table 1. Activated HBV-, HCMV-, EBV- and Flu-specific CD8 T cells in HBV acute patients where HBV, HCMV, EBV and Influenza
specific cells could be visualized with pentamers.
Patients (HBV Acute) CD38+/HLA-DR+CD8+ T cells % (absolute number/10 ml)
Total CD8 HBV HCMV EBV FLU
P 7 18% (738) 81% (108) 5.5% (2) n f n f
P 9 18% (720) 43% (14) 13% (10) n f n f
P 10 25% (940) 77% (9) 20% (20) n f 0% (0)
P 11 21% (800) 81% (54) n f n f 0.9% (0)
P 12 28% (1218) n f 8% (9) 41% (12) n f
P 13 17% (700) n f n f 31% n f
P 22 17% (700) n f n f n f 2% (0)
P 23 15% (880) n f 12% n f 1.3% (0)
P 24 26% (1066) 89% 20% n f 1.4% (0)
P 25 12% (710) n f 9% (10) 26% (9) 0% (0)
P 26 68% (n.d.) n f n f 22% (n d) n f
P 27 16% (n d) n f n f n f 0.2% (n d)
P2 8 2 1 %( nd ) nf nf nf 0 %( nd )
Average 23% 74% 12.5% 30% 0.7%
Percent of activated virus-specific CD8 T cells are shown and the number of cells in 10 ml of blood, calculated based on the pentamer frequency and lymphocyte count
in the blood of patients at the acute stage.
n f = not found; n d = not done.
doi:10.1371/journal.ppat.1001051.t001
Table 2. Proliferating HBV-, HCMV-, EBV- and Flu-specific CD8
T cells in HBV acute patients where HBV, HCMV, EBV and
Influenza specific cells could be visualized with pentamers.
Patients
(HBV Acute) Ki-67+ CD8+ T cells % (absolute number/10 ml)
Total CD8 HBV HCMV EBV FLU
P 7 19% (738) 85% (112) 2% (1) n f n f
P 9 6% (240) 10% (6) 2.4% (2) n f n f
P 10 16% (564) 65% (8) 6% (6) n f 0% (0)
P 11 17% (560) 67% (40) n f n f 0.1% (0)
P 1 2 n d n f n dn dn f
P 13 16% (739) n f 9% (12) 11% (1) n f
P 2 2 n d n f n fn fn d
P2 3 nd nf nd nf nf
P2 4 nd nd nd nf nd
P 25 12% (520) n f n d 5% (0.2) 0% (0)
P2 6 nd nf nf nd nf
P 27 18% (n d) n f n f n f 2.5% (n d)
P 28 27% (n d) n f n f n f 0% (n d)
Average 16% 57% 4.9% 8% 0%
Percent of proliferating virus-specific CD8 T cells are shown and the number of
cells in 10 ml of blood, calculated based on the pentamer frequency and
lymphocyte count in the blood of patients at the acute stage.
n f = not found; n d = not done.
doi:10.1371/journal.ppat.1001051.t002
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PLoS Pathogens | www.plospathogens.org 5 August 2010 | Volume 6 | Issue 8 | e1001051Figure 4. Activation of CD8 T cells in different acute viral infections. A) Kinetics of the expansion of CD38/HLA-DR expressing CD8 T cells in
acute HBV (n=20), dengue (n=12), influenza A (n=12), adenovirus (n=3) infected patients. B) Frequencies of total CD8 T (upper panel) and HCMV
and EBV-specific CD8 T cells (lower panel) expressing CD38/HLA-DR at the onset of acute viral infections. The number of patients in whom HCMV and
EBV CD8 T cells were sizeable is indicated by digits. The arrow indicates activation levels of healthy controls (n=5). C) Discordant kinetics of activated
total CD8 T cells and influenza-A specific CD8 T cell frequency in one patient (P14). Contour plots represent the phenotype of total CD8 T cells (upper
panel) and of HCMV-specific (pp65, 495–504) CD8 T cells (lower panel). The middle panel displays the frequencies of HCMV-pentamer+ CD8 T cells.
doi:10.1371/journal.ppat.1001051.g004
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IL-15
We investigated the possible mechanisms of the selected
activation of HCMV and EBV- specific CD8 T cells in patients
with heterologous acute viral infections.
CD8 T cell cross-reactivity, reactivation of the HCMV or EBV
infection and/or activation mediated by cytokines can be
implicated in this phenomenon.
Cross-reactivity between HCMV or EBV-specific CD8 T cells
with epitopes present in the acute heterologous virus infection
seems unlikely. The cross-reactive potential of HCMV-specific
CD8 T cells is very uncommon [7] and our data do not support
cross-reactive mechanisms either. We could detect activation of
CD8 T cells specific for two distinct immediate early and latent
EBV epitopes (HLA-B8 RAKFKQLL, BZLF-1 190–197, and
HLA-B8 FLRGRAYGL, EBNA-3A 193–201) in an acute HBV
patient (Supplementary Figure S2). If cross-reactivity was
responsible of this activation, it would require that both epitopes
share sequence or structural similarity with HBV virus, an unlikely
scenario, based on a sequence similarity search (NCBI PubMed
BLAST), which demonstrated no sequence overlap (lowest E value
obtained =11) between these EBV epitopes and HBV proteome.
Reactivation of HCMV and EBV could be a plausible cause,
and it might explain why CD8 T cells specific for Influenza are not
activated in acute HBV infections. To investigate this possibility,
HCMV and EBV DNA levels were tested longitudinally in the
serum. However, we did not find any evidence of HCMV or EBV
reactivations. HCMV-DNA and EBV-DNA titers were below the
level of detection in all patients (HBV, Dengue, Influenza,
Adenovirus and fever of unidentified etiology) from the onset of
acute heterologous viral infections to recovery (data not shown).
Importantly, although HCMV and EBV reactivations are usually
associated with the expansion of HCMV/EBV- specific CD8 T
cells [10,17,18] significant changes in the EBV or HCMV specific
T cells quantity were not observed through the course of acute
infections (Figure 3 B and Supplementary Figure S2).
We therefore analyzed whether cytokines produced during
acute viral infections [19] can be responsible for the differential
expression of activation markers by EBV-, HCMV- and influenza-
specific CD8 T cells.
PBMC or purified CD8 T cells of healthy subjects containing
resting EBV, HCMV and Influenza specific CD8 T cells were
incubated with different concentrations of IL-15, IL-2, IL-7, IFN-
c, IFN-a and TNF-a and the expression of HLA-DR and CD38
on EBV, HCMV and Influenza specific CD8 T was analyzed at
different intervals (Figure 5 A). We detected that after 24 and
48 hours of incubation, IL-15 (at 1 and 10 ng/ml) induced CD38/
HLA-DR expression in HCMV and EBV specific CD8 T cells
while the other inflammatory cytokines did not activate EBV and
HCMV specific CD8 T cells. Similar to the in vivo findings,
influenza-specific CD8 T cells were not or only weakly activated
by addition of any of the tested cytokines (Figure 5 A and B).
Prolonged incubation times (3 to 5 days) did not alter the
activation profile. Figure 5 B shows the results obtained in one
healthy subject where HCMV, EBV and Influenza specific CD8 T
cells were simultaneously detected. Incubation of total PBMC with
IL-15 induces expression of CD38/HLA-DR molecules in EBV
and HCMV specific CD8 T cells (44% and 37% respectively) but
only in few influenza-specific CD8 T cells (7%). The specific effect
of IL-15 on HCMV and EBV-specific CD8 T cells was confirmed
in other healthy subjects where individual specificities were
detected (HCMV= n4; EBV= n4). Similar results were obtained
incubating total PBMC or CD3+ CD8+ purified cells (not shown).
Thus, IL-15, a cytokine that has been shown to induce T cell
activation in mice [20] and human [21,22] and is known to be
produced during acute viral infections ([19] and personal data)
induces preferential CD38, HLA-DR up-regulation of HCMV
and EBV-specific CD8 T cells rather than influenza-specific ones.
Functional analysis of HCMV and EBV-specific CD8 T cells
during acute heterologous viral infections
Having observed that a proportion of HCMV and EBV-specific
CD8 T cells are activated during heterologous acute viral
infection, we sought to analyze their functional profile. The
limited quantity of cells available in patients with acute viral
infections precludes an extensive evaluation of the functional
profile directly in our patient sample. Thus, since IL-15 mimics the
differential activation state of HCMV, EBV and influenza-specific
CD8 detected in patients with acute viral infections, we performed
a series of functional experiments using PBMC of healthy
individuals activated with IL-15.
We first tested whether IL-15 can differentially trigger T cell
activation in HCMV, EBV and Influenza specific CD8 T cells in
vitro. PBMC of healthy individuals were incubated with or without
IL-15 for 48 hours and HCMV, EBV and influenza-specific CD8
T cells were tested for their ability to produce anti-viral cytokines
(IFN-gamma, IL-2 and TNF-alpha) using intracellular cytokine
staining. Note that the cytokines measurement on CD8 T cells
specific for the different viruses requires their visualization with the
specific HLA-class I/peptides pentameric complex (pentamers).
The pentamer staining can potentially trigger T cell stimulation
through direct interaction of the TCR with the synthetic MHC-
class I peptide complexes of the pentamers[23,24,25]. Thus, to
distinguish whether IL-15 can directly trigger T cell activation
(TCR-independent stimulation) or enhance the T cell activation
triggered by MHC/peptide pentamer (TCR-dependent stimula-
tion), the intracellular production of IFN-gamma on CD8 T cells
was analyzed adding the MHC/peptide pentamers either before
(TCR-dependent stimulation) or after (TCR-independent stimu-
lation) the incubation time of intracellular cytokine staining. A
schematic representation of the experimental design is presented in
Figure 6 A.
In accordance with previous studies [21,22], IL-15 elicited a
spontaneous production of IFN-gamma on T cells. However, the
level of IFN-gamma production was modest and present in CD8
cells irrespective of their specificity. Dot plots displayed in Figure 6
A illustrate these results obtained in one representative subject.
Increased production of other cytokines (IL-2, TNF-alfa) was less
striking (not shown).
In contrast, we observed that HCMV and EBV-specific CD8 T
cells incubated with IL-15 and stained with MHC/peptide
pentamer at the beginning of the intracellular cytokine assay
showed an increased ability to produce IFN-gamma. More than
70% of IL-15 pulsed HCMV and EBV-specific CD8 T cells
produced high quantity of IFN-gamma while in the absence of IL-
15, MHC-pentamer staining stimulate only a minority of HCMV
and EBV-specific CD8 cells (Figure 6 A–B). Importantly, IL-15
incubation has a modest effect on Influenza specific CD8 T cells
(Figure 6 A–B). Thus, our in vitro experiments showed that IL-15
is not only able to preferentially activate HCMV and EBV-specific
CD8 T cells, but can also modulate their functional responsiveness
to the TCR-dependent stimulation mediated by MHC-pentamer
staining.
Having defined a different functional profile on in vitro activated
HCMV and EBV-specific CD8 T cells, we tested whether such
features could be detected in vivo.
In line with the experiments in vitro, MHC-peptide pentamer
stimulation was detected preferentially on HCMV and EBV-
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(Figure 6 C and D).
Figure 6 C shows the results obtained in a representative patient
(P24) with acute hepatitis and with a sizeable population of
activated HCMV-specific CD8 T cells (20%). While the
spontaneous production of IFN-gamma was identical in HCMV-
specific CD8 cells present at the onset and at recovery of acute
hepatitis B (Figure 6 C- unstimulated), 12% of HCMV specific
CD8 cells present at the onset of acute hepatitis B against only 4%
of the ones present at recovery produced IFN-gamma after MHC-
pentamer stimulation (Figure 6 C). In addition to the higher
frequency of IFN-gamma producing cells, the amount of the
cytokine produced during the onset was higher than that during
the resolution, as visualized by the difference in mean fluorescence
intensity (MFI) (1152 at onset and 507 resolution).
Figure 6 B shows the cumulative results obtained in 6 subjects
with detectable HCMV (P9, P10, P7, P24), EBV- (P13) and
influenza-specific CD8 (P24, P11) at the onset and recovery of
acute hepatitis B. Bars indicate the % increase of IFN-gamma
producing CD8 T cells at onset of acute hepatitis in comparison
with recovery.
Thus, persistent virus specific CD8 T cells produce more anti-
viral cytokines after TCR-mediated activation during acute phase
of heterologous viral infection.
Discussion
We demonstrate here that activation of CD8 T cells specific for
persistent viral infection (HCMV-EBV) is a constitutive feature of
acute anti-viral immunity in human.
Figure 5. IL-15 induced activation of HCMV and EBV-specific CD8 T cells. A) PBMC of 4 healthy volunteers were incubated with IL-15 (10 ng/
ml), IL-2 (20 U/ml), IL-7 (10 ng/ml), IFN-c (100 U/ml), IFN- a (100 U/ml), TNF- a (100 U/ml). Cells were harvested at the indicated time points and
frequency of CD38/HLA-DR expressing virus specific CD8 T cells was analyzed. B) Contour plots show the CD38/HLA-DR expression of EBV, HCMV or
Influenza specific CD8 T cells after 48 hours of incubation with the indicated cytokines in a representative healthy subject.
doi:10.1371/journal.ppat.1001051.g005
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PLoS Pathogens | www.plospathogens.org 8 August 2010 | Volume 6 | Issue 8 | e1001051Figure 6. Functional analysis of HCMV and EBV-specific CD8 T cells during acute heterologous viral infections. A) Schematic
representation of experimental design: PBMC from healthy volunteers were incubated for 48 h in presence or absence of IL-15. Cells were then
collected, incubated with pentamer or in PBS for 15 min, washed and incubated for 5 h in presence of Brefeldin A. Following the 5 h incubation the
cells were collected and the unstimulated cells, those that have not been stained with pentamer prior to BFA incubation, were stained with pentamer
for 15 min. Then the cells were washed and ICS performed. The expression of IFN-c in EBV-pentamer+ (EBNA-1 407–417, +EBNA4, 416–424), HCMV-
pentamer+ (pp65 495–504) and Flu-pentamer+ (MP, 58–66) CD8 T cells is shown. Histogram plots gated on CD3+ CD8+ pentamer + cells (contour
plots) of one representative healthy individual are shown. B) Percent of IFN-c+ MHC/peptide pentamer stimulated HCMV-, EBV- and Flu-specific CD8 T
cells is shown based on gating for unstimulated cells cultured without cytokine. C) Histogram plots representing IFN-c production of unstimulated
and MHC/peptide pentamer stimulated HCMV-pentamer+ (pp65 495–504 + pp65 123–131) CD8 T cells in a representative HBV acute patient. D)
Percent increase of IFN-c production by MHC-peptide pentamer stimulated HCMV-, EBV- and Flu-specific CD8 T cells during the onset of acute HBV
infection compared to the resolution.
doi:10.1371/journal.ppat.1001051.g006
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virus recipients [13], which have suggested that activated (CD38/
HLA-DR+) and proliferating (Ki-67+) CD8 T cells are exclusively
constituted of CD8 T cells specific for the acutely infecting virus.
However, our patients with activated/proliferating HCMV and
EBV responses had a symptomatic viral infection with a high level
of inflammation, whereas those subjects vaccinated with attenu-
ated viruses, by definition, should not exhibit any pathology of
acute infection.
Of note, the presence of activated HCMV and EBV specific
CD8 was also detected during other pathological human viral
infections [14,26,27] further supporting our conclusion that
activation of CD8 T cells specific for persistent infection is a
consistent phenomenon during symptomatic viral infections.
In contrast to HCMV and EBV-specific CD8 cells, we
observed that CD8 T cells specific for influenza were not
activated during the acute phase of heterologous acute viral
infection. Thus, our data show that memory CD8 cells specific
for persistent and non-persistent viruses not only differs in term of
phenotypic profile in healthy individuals [28], but respond
differently to the pathological condition triggered by an
heterologous acute viral infection.
We can only speculate about the causes of the variable behavior
of CD8 T cells specific for the different pathogens. A plausible
explanation is that, while influenza-specific CD8 T cells are true
memory CD8 cells without any recent encounter to their specific
ligand, EBV and HCMV specific CD8 cells might experience a
continuous or repetitive exposure to the specific antigens.
The accumulation over time of herpesvirus-specific CD8 T cells
in healthy subjects [29,30] and work in animal model of HCMV
infection [31], have suggested that EBV and HCMV antigens are
constantly available for T cell stimulation. The Ag-exposure might
modulate the functional state of HCMV and EBV-specific CD8
cells and program them to respond to cytokines produced during
acute viral infections. The differential functional state of
herpesvirus specific CD8 T cells when compared with influenza-
specific was confirmed by our in vitro data. We clearly demonstrate
that IL-15 triggers in vitro the activation/proliferation of HCMV,
EBV specific rather than influenza-specific CD8 T cells.
Based on these in vitro data, we favor the idea that the detection of
activated/proliferating HCMV and EBV specific CD8 T cell is
mediated principally by the presence of IL-15 during acute phase of
viral infections. This makes HCMV/EBV reactivation or indeed
cross-reactivity a less likely explanation for this phenomenon.
However, it is important to stress that this causative link is
hypothetical since the level of IL-15 required to activate HCMV/
EBV in vitro (1–10 ng/ml) is higher than what we detected in the
serum of the patients in this study (always lower then 50 pg/ml in any
viral infection, data not shown). Such inconsistency should be taken
into account, even though the serum cytokine levels cannot define
their actual concentrations in the target organ or lymph node.
We cannot exclude that a reactivation of EBV/HCMV
infection is occurring in our patient population and thus directly
driving the HCMV or EBV-specific CD8 T cell activation. We
couldn’t demonstrate any virological evidence of HCMV and
EBV reactivation, but the negative virological tests do not exclude
a HCMV and/or EBV viral reactivation is present elsewhere
outside the blood compartment and is immediately curtailed by
activated HCMV and EBV specific CD8 T cells. A similar
scenario was suggested to occur in patients with acute Hantavirus
infection where an increased EBV-DNA titers were found only in
subjects without measurable EBV-specific T cell response [26].
However, it has been reported that HCMV and EBV reactivation
is associated with the expansion of HCMV/EBV specific CD8 T
cells [10,17,18], which was not observed in any of our patients
(Figure 3 B and Supplementary Figure S2).
What appears clear from our data is that the contribution of the
activated/proliferating HCMV/EBV specific CD8 T to the size of
activated total CD8 T cells is not negligible, but at the contrary
can alter the quantitative measurement of anti-viral CD8 T
response during acute viral infections. A mean of, respectively,
30% and 12.5% of EBV and HCMV-specific CD8 T cells express
activation markers during the acute phase of different viral
infections and since the combined population of both HCMV-
EBV specific CD8 T cells might exceed 20% of total CD8 T cells
[7,9] it is plausible to conclude that EBV/HCMV-specific CD8 T
cells can inflate the number of total activated CD8 T cells.
The presence of activated/proliferating CD8 T cells specific for
HCMV and EBV during the early phases of different acute viral
infection raises several questions. First, it will be interesting to
evaluate whether CD8 T cells specific for other persistent viruses
(i.e. HSV1 and 2) can actually behave like HCMV or EBV specific
CD8 T cells and thus further contribute to the anti-viral CD8 T
cell acute response.
A further question might address the biological significance of
the herpesvirus specific CD8 T cell activation during heterologous
acute viral infections.
There is a possibility that the activation/proliferation state of
HCMV/EBV specific CD8 T cells counteracts the potential
attrition exerted by the expansion of CD8 T cells specific for the
acutely infecting virus [32] and therefore might be important for
preventing the reactivation of HCMV/EBV infection. In this
regard, our data differ from previous reports in acute HBV
infected patients [33], since we did not observe any significant loss
of HCMV or EBV specific CD8 T cells. On the contrary, HCMV
and EBV-specific CD8 T cell frequency was remarkably constant
during the different phases of acute heterologous viral infections
and the observed mild proliferation of HCMV and EBV specific
CD8 T cells (Figure 3 A and Supplementary Figure S2) might
represent a compensatory mechanism counteracting the attrition
exerted by the expansion of CD8 T cell specific for the acutely
infected virus [30,34].
In addition, the observation that activation of HCMV and EBV
specific CD8 T cells present during the acute phase of
heterologous viral infections is associated with a functional
increase in the MHC-pentamer mediated CD8 T cell activation
further supports the idea that such events might have a broader
biological significance.
We can only speculate about the physiological significance of
the increased MHC-pentamer mediated CD8 T cell activation.
However, a plausible interpretation is that the HCMV and EBV-
specific CD8 cells during acute heterologous viral infection are less
dependent to possible co-stimulatory effect mediated by additional
molecules provided by their target during T cell recognition.
Alternatively, the increased response to pentamer-mediated
staining might indicate a lower requirement of MHC-class I
complexes necessary for T cell activation [24]. These various
possibilities will need further investigation, but what our data
clearly demonstrate is that functional differences in the ability to
produce IFN-gamma are present in different phases of heterolo-
gous acute viral infection.
The increased likelihood of activated HCMV, EBV specific CD8
T cells to produce antiviral cytokines after recognition of HCMV
and EBV antigens might be beneficial not only in the control of
HCMV/EBV reactivation but can actively contribute to the global
anti-viral immune response. Evidences in animal model have
already shown that T cell activation of non-antigen specific T cells
can contribute to the early response against pathogens [12,35].
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HCMV and EBV- specific CD8 T cells can have an impact on
immunopathogenesis of the viral infections [36]. Heterologous
immunity have been observed to alter pathogenesis of different
viral diseases [37,38].
In conclusion, we show that the CD8 T cell population
activated during acute viral infection is not constituted exclusively
by CD8 T cells specific for the newly infected virus. On the
contrary, this population is inflated by the presence of activated T
cells specific for herpesvirus, directly demonstrating the ability of
persistent virus infections to leave a functional imprint on the acute
anti-viral T cell response in humans with functional consequences
that will require further elucidation.
Methods
Patients and samples
Samplesweretaken from patients or healthy volunteers attending
clinics in Singapore (Dengue, Influenza, Adenovirus infections,
fevers of unidentified etiology and healthy volunteers) and Italy
(HBV infection). Local Review board and Ethical Committees
approved the study. Total number of patients is 50: HBV 20,
Influenza 12, Dengue 12, Adenovirus 3, patients with fevers of
unidentified etiology 3. Number of healthy volunteers enrolled is 5.
Age of the subjects ranged from 20 to 54 years old. Patients were
selected on the basis of fever .38uC (Dengue, Influenza,
Adenovirus) or jaundice (HBV). Diagnosis of dengue (detection of
dengue virus by PCR), influenza A (+ isolation of influenza A from
nasal swab), adenovirus (isolation of the virus from nasal swab), and
HBV (HBsAg +, anti-HBc IgM+ and HBV-DNA+) was performed
within 5 days from selection. Acute hepatitis B patients were all
HBsAg+ and hadALT.1000 U/L, at the disease onset.Allhealthy
volunteers were asymptomatic. Peripheral blood mononuclear cell
isolation from whole heparinized or EDTA blood with Ficoll-
Hypaque was performed within 4 hours of drawing. PBMC were
analyzed immediately or frozen for subsequent analysis.
Virological measurements
HBV patients: HBsAg, HBeAg, anti-HBs, anti-HBc IgG and
IgM, anti-HBe, anti-HDV, anti-HCV, anti-HIV-1 and -2 were
determined by commercial enzyme immunoassay kits (Abbott Labs,
IL, USA; Ortho Clinical Diagnostic, Johnson & Johnson, DiaSorin,
Vercelli, Italy). HBV-DNA was quantified by PCR (Cobas
Amplicor test; Roche Diagnostic, Basel, CH) and CMV-DNA was
quantified with artus-CMV-LC PCR (Qiagen, Qiagen Gmbh,
Hilden), EBV-DNA was tested with EBV R-gene DNA extraction
and quantification kit (Argene, Varilhes, France). Dengue detection
was performed by RNA isolation from serum samples using RNA
extraction kit followed by reverse-transcription into cDNA
(Superscript III First Strand kit, Invitrogen, California, USA). The
cDNA was PCR amplified for detection of the virus, for
determination of serotype and for quantification of viral load as
previously published [39]. The serum and nasal swab samples were
tested for the presence of Influenza A and Adenovirus using RT-
PCR (Superscript III First Strand kit, Invitrogen, California, USA)
and direct immunofluorescence assay on nasal swabs (Light
Diagnostic Influenza A antibody FITC reagent, Millipore, Billerica,
MA). Amino acid sequence alignment was done using BLAST from
NCBI PubMed (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Reagents
HLA-peptide pentameric complexes (pentamers) were pur-
chased from Proimmune (Oxford, UK). Anti-CD8 (PE-Cy7 and
APC-Cy7), anti-CD3 (perCP and perCP-Cy5.5) anti-CD38 (APC),
anti-HLA-DR (Pe-Cy7), anti-KI-67 (FITC and PE), anti-Bcl-2
(FITC), anti-IFN-c (FITC and APC), anti-IL2 (FITC, PE and
APC), and isotype control antibodies were purchased from BD
Biosciences, San Jose, CA.
Phenotypic analysis
Titrated pentamers (PE) were added to 50 ml of purified PBMC
(2610
6 cells total) for 15 min at 25uC in the dark, washed and then
panel of titrated antibodies for surface markers were added to
pentamer stained or total PBMC. The cells were then fixed and
permeabilized using Cytofix/Cytoperm solution (BD Biosciences,
San Jose, CA). After washing, intracellular staining was performed
for intracellular markers (Ki-67, Bcl-2). Cells were then washed
3 times, and fixed with 1% formaldehyde before acquisition on a
FACS Canto flow cytometer. Compensation was checked
regularly using FASC Diva software. Compensation controls were
individually determined for each experimental setup.
Functional assays
PBMC were stained with the relevant pentamers (MHC/
peptide pentamer stimulated), or left unstained (unstimulated),
washed and then incubated for 5 h with 10 mg/ml brefeldin A
(Sigma-Aldrich, St. Louis, MO). Following incubation, the
unstimualted cells were stained with relevant pentamers and
MHC/peptide pentamer-stimulated were left in PBS. Then cells
were stained with anti-CD8 and anti-CD3 mAbs for 20 min at
4uC then fixed and permeabilized using Cytofix/Cytoperm
solution. Finally, cells were stained with anti-IFN-c and anti-IL-
2 for 30 min on ice, washed, and fixed with 1% formaldehyde
before acquisition on a FACS Canto flow cytometer. For analysis
of anti-virus-specific CD8 T activation in vitro, freshly isolated
PBMC or purified CD8+ T cells were incubated in vitro at
2610
6/ml with or without cytokines (IL-7, IL-2, IL-15, IFN-c,
IFN- a, TNF- a, purchased from RnD Systems, Minneapolis,
MN). The cells were collected at indicated time points, and the
intracellular cytokine staining was performed as described above.
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Singapore National Healthcare
Group Ethical Domain and Azienda Ospedaliera Universitaria di
Parma Ethical Committee hospitals. All patients provided written
informed consent for the collection of samples and subsequent
analysis.
Supporting Information
Figure S1 Different activation markers expression profiles of
Influenza, HCMV-specific and HBV-specific CD8+ cells present
in a representative patient at the onset of acute hepatitis B.
Found at: doi:10.1371/journal.ppat.1001051.s001 (1.28 MB TIF)
Figure S2 A) Quantity of CMV, EBV and Flu specific CD8 T
cells do not change during heterologous acute viral infections.
PBMCs of acute HBV and Influenza patients from three time
points of the disease were stained with pentamers specific for
CMV, EBV and Flu and with anti-CD3, anti-CD8 monoclonal
antibodies. The quantity of pentamer+ cells were determined
based on the frequency of pentamer CD8 T cells and the
lymphocyte counts. B) Activation of two distinct epitopes of EBV
during acute hepatitis B. PBMCs of acute HBV patient were
stained with two EBV pentamers (BZLF1 190-197 and EBNA3A
193-201) and CD3, CD8, CD38, HLA-DR surface markers.
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Table S1 Pentamers for HBV, EBV, HCMV and Influenza A
Found at: doi:10.1371/journal.ppat.1001051.s003 (0.03 MB
DOC)
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